CLAIMS

1. Use of (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a serotonin reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor and an antianxiety drug,
in the manufacture of a medicament for the treatment of a central nervous system disease selected from the group consisting of emotional disturbance, bipolar disorder, bipolar disorder type I, bipolar disorder type II, mania, depression, endogenous depression, major depression, melancholic and treatment-resistant depression, anxiety disorder, panic attack, panic disorder, agoraphobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, and acute stress disorder,
wherein said compound (I) and said drug of (II) are to be administered in a single drug formulation, or in separate formulations to be administered simultaneously or at different time points.

2. The use of claim 1, wherein said drug (II) is a serotonin reuptake inhibitor.

3. The use of claim 2, wherein said serotonin reuptake inhibitor is at least one drug selected from the group consisting of fluoxetine, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.

4. The use of claim 1, wherein said drug (II) is a serotonin and norepinephrine reuptake inhibitor.

5. The use of claim 4, wherein said serotonin and norepinephrine reuptake inhibitor is at least one drug selected from the group consisting of venlafaxine, duloxetine, milnacipran, desvenlafaxine and salts thereof.

6. The use of claim 1, wherein said drug (II) is an antianxiety drug.

7. The use of claim 6, wherein said antianxiety drug is at least one drug selected from the group consisting of diazepam, lorazepam, chlordiazepoxide, cloxazolam, clotiazepam, alprazolam, etizolam, oxazolam, tandospirone, buspirone and salts thereof.

8. Use of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof in the manufacture of a medicament for the treatment of a central nervous system disease selected from the group consisting of emotional disturbance, bipolar disorder, bipolar disorder type I, bipolar disorder type II, mania, depression, endogenous depression, major depression, melancholic and treatment-resistant depression, anxiety disorder, panic attack, panic disorder, agoraphobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, and acute stress disorder in a patient being administered with at least one drug selected from the group consisting of a serotonin reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor and an antianxiety drug.

9. The use of claim 8, wherein said drug (II) is a serotonin reuptake inhibitor.

10. The use of claim 9, wherein said serotonin reuptake inhibitor is at least one drug selected from the group consisting of fluoxetine, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.

11. The use of claim 8, wherein said drug (II) is a serotonin and norepinephrine reuptake inhibitor.

12. The use of claim 11, wherein said serotonin and norepinephrine reuptake inhibitor is at least one drug selected from the group consisting of venlafaxine, duloxetine, milnacipran, desvenlafaxine and salts thereof.

13. The use of claim 8, wherein said drug (II) is an antianxiety drug.

14. The use of claim 13, wherein said antianxiety drug is at least one drug selected from the group consisting of diazepam, lorazepam, chlordiazepoxide, cloxazolam, clotiazepam, alprazolam, etizolam, oxazolam, tandospirone, buspirone and salts thereof.